Caris Life Sciences (CAI) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 revenue of $216.8 million, up 113% year-over-year, with net income of $24.3 million and positive adjusted EBITDA of $51.2 million, driven by strong clinical profiling and new product launches.

• Clinical case volume grew 18.2% to 50,763, with clinical ASP up 87% to $4,089 per profile.

• Gross margin improved to 68% from 43.7% a year ago, and free cash flow was $55.3 million.

• Completed IPO in June 2025, raising $519.5 million in net proceeds and converting all preferred stock and convertible notes.

• Strategic focus remains on expanding precision medicine, early detection, and leveraging AI and data platforms.

Financial highlights

• Total revenue reached $216.8 million, up 113% year-over-year; molecular profiling revenue grew 121% to $207.6 million; pharma R&D services revenue up 18% to $9.2 million.

• Gross margin expanded to 68% from 43.7% in Q3 2024.

• Adjusted EBITDA was $51.2 million; net income $24.3 million; free cash flow $55.3 million.

• Cash and investments increased to $759.3 million as of September 30, 2025.

• Clinical profiling ASP rose 87% year-over-year to $4,089 per profile.

Outlook and guidance

• FY25 revenue guidance raised to $720–$730 million, a 75–77% increase over 2024.

• Clinical therapy selection volume growth expected at 21–22% for the year.

• Q4 revenue guidance set at $200–$210 million, with pharma revenue expected at $20–$30 million.

• Full-year gross margin expected to reach 62%, up from 43.4% in 2024.

• Q4 tissue ASP expected around $3,600; blood ASP guidance raised to $2,300–$2,400 per case.